Regeneron Pharmaceuticals Inc (REGN) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $2.57 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $2.55. The company posted revenue of $1201.00 million in the period, compared to analysts expectations of $1178.39 million. The company’s revenue was up 38.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.88 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016. Shares were Reiterated by Sun Trust Rbsn Humphrey on Mar 17, 2016 to “Neutral” and Lowered the Price Target to $ 410 from a previous price target of $450 .Shares were Downgraded by Chardan Capital Markets on Mar 16, 2016 to ” Sell” and Lowered the Price Target to $ 325 from a previous price target of $375 .
Regeneron Pharmaceuticals Inc closed down -10.68 points or -2.88% at $360.64 with 10,08,826 shares getting traded on Wednesday. Post opening the session at $370.06, the shares hit an intraday low of $360.25 and an intraday high of $371.09 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Apr 7, 2016, Joseph L Goldstein (director) sold 2,000 shares at $425.00 per share price. According to the SEC, on Dec 29, 2015, Douglas S Mccorkle (VP Controller and Asst Treasur) sold 3,954 shares at $552.08 per share price. On Dec 11, 2015, Michael S Brown (director) sold 3,000 shares at $545.37 per share price, according to the Form-4 filing with the securities and exchange commission.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.